Latisse a Happy Accident for Allergan and Women With Inadequate Eyelashes
Latisse is currently the only FDA-approved treatment for eyelash hypotrichosis, abnormal or inadequate eyelash growth. Latisse is thought to work by increasing the number of eyelashes your eyelid can sprout and extending their growth cycle.

LOS ANGELES, CA, May 26, 2011 /24-7PressRelease/ -- Allergan seems to have a history of happy accidents.

The specialty pharmaceutical company came across the wrinkle-smoothing benefits of BOTOX while testing the compound as a treatment for eyelid spasms. Then it stumbled onto the eyelash-stimulating abilities of bimatoprost, a topical glaucoma medication that became the active ingredient in Latisse.

Latisse is currently the only FDA-approved treatment for eyelash hypotrichosis, abnormal or inadequate eyelash growth. Latisse is thought to work by increasing the number of eyelashes your eyelid can sprout and extending their growth cycle.

The result in a majority of Latisse users is eyelashes of increased length and volume. Latisse is available only by prescription, but when applied according to direction, most users see full results within two months of treatment.

The effects of Latisse, however, are not permanent. You must maintain regular use or your eyelashes will return to their original appearance.

Latisse is not for everyone, and you should consult a doctor and certified Latisse provider to determine if Latisse is right for you. Side effects from Latisse are rare and include itchy, red and/or dry eyes. In some cases, excessive hair growth around the eyes has occurred if Latisse regularly drips during the application. Some users have reported hardening of the eyelid skin where Latisse is applied, and others have experienced a darkening of pigmentation in the iris.

Press Release Contact Information:

Sara Goldstein
ePR Source
submission staff
17301 W. Colfax Ave Suite 275
Golden, CO
United States 80401
Voice: 3032333886
Website: Visit Our Website